Senior Director, National and Strategic Accounts

<div class="content-intro"><p>Olema Oncology is <span data-ccp-parastyle="Normal (Web)">a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with </span><span data-ccp-parastyle="Normal (Web)">breast cancer</span><span data-ccp-parastyle="Normal (Web)"> and beyond.</span><span data-ccp-parastyle="Normal (Web)"> </span><span data-ccp-parastyle="Normal (Web)">It’s</span><span data-ccp-parastyle="Normal (Web)"> an exciting time to be part of Team Olema</span><span data-ccp-parastyle="Normal (Web)">,</span><span data-ccp-parastyle="Normal (Web)"> with</span><span data-ccp-parastyle="Normal (Web)"> </span><span data-ccp-parastyle="Normal (Web)">our transfor</span><span data-ccp-parastyle="Normal (Web)">mation into a fully</span><span data-ccp-parastyle="Normal (Web)"> </span><span data-ccp-parastyle="Normal (Web)">integrated oncology company well underway</span><span data-ccp-parastyle="Normal (Web)">, </span><span data-ccp-parastyle="Normal (Web)">t</span><span data-ccp-parastyle="Normal (Web)">op-line data from our lead program expected </span><span data-ccp-parastyle="Normal (Web)">later </span><span data-ccp-parastyle="Normal (Web)">this </span><span data-ccp-parastyle="Normal (Web)">year</span><span data-ccp-parastyle="Normal (Web)">,</span><span data-ccp-parastyle="Normal (Web)"> </span><span data-ccp-parastyle="Normal (Web)">and our first potential commercial launch on the horizon.</span></p>

<p><span data-contrast="auto"><span data-ccp-parastyle="Normal (Web)">Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from OPERA-01, our ongoing Phase 3 trial of palazestrant as a monotherapy in patients with second- or third-line ER+/HER2- metastatic breast cancer (MBC), in the fall which, if successful, could lead to our first potential approval and commercial launch in 2027. OPERA-02, our Phase 3 trial of palazestrant in combination with ribociblib in patients with frontline ER+/HER2- MBC, is enrolling patients. Together with its mechanism of action, pharmacokinetic properties, and the potential to demonstrate activity in both ESR1 wild-type and mutant tumors, palazestrant has the potential to transform the metastatic breast cancer treatment paradigm and access a $15 billion global market opportunity.</span></span></p>

<p><span data-contrast="auto"><span data-ccp-parastyle="Normal (Web)">Our follow-on product candidate, OP-3136, is a potent KAT6 inhibitor with the potential to generate further value and meaningfully impact the metastatic breast cancer treatment landscape – particularly in combination with palazestrant. We recently reported encouraging Phase 1 monotherapy data from this program across multiple solid tumor types and are advancing patient enrollment in the ongoing combination arms in MBC.</span></span></p>

<p><span data-contrast="auto">Aspiring to transform the metastatic treatment paradigm is an ambitious endeavor that requires a resolute approach to developing better therapies and a passionate team dedicated to helping the patients we serve feel better, longer. We possess a deep commitment to our shared purpose, the sustained pursuit of excellence, cultivating the courage required to advance our programs, drive to succeed, and a collective capacity for adaptability through learning, growth, and evolution.  Team Olema is made up of nimble self-starters who bring consistency in their quest for the extraordinary every single day.</span></p>

<p>If you’re ready to be part of a tenacious, courageous, agile, and growing team, join us in making a profound impact, together – <strong><span data-contrast="auto">for <span data-ccp-charstyle="Strong">our patients, for your career, </span><span data-ccp-charstyle="Strong">and </span><span data-ccp-charstyle="Strong">for </span><span data-ccp-charstyle="Strong">what’s</span><span data-ccp-charstyle="Strong"> beyond</span></span></strong><span data-contrast="auto">.</span></p></div><p><strong><span data-contrast="auto">About the Role >>> S</span></strong><strong><span data-contrast="auto">enior</span></strong><strong><span data-contrast="auto"> Director, National and Strategic Accounts</span></strong><strong><span data-contrast="auto"> </span></strong></p>

<p><span data-ccp-props="{}"> </span><span data-contrast="auto">The Senior Director, National and Strategic Accounts will be a key member of the Market Access leadership team and will be responsible for the development of the Market Access Payer strategic plan and vision for business opportunities in various national and regional markets to support the launch of first product, palazestrant, along with future indications and additional therapies.  Reporting to the Vice President of Market Access, the Senior Director will be both a strategic and tactical expert in the areas of Market access, payer coverage, and contracting and possess an intimate knowledge of the business of oncology and of the makeup of the provider accounts and networks. You will work as a functional leader, a strategic thinker, and a team member with the ability to execute a national and regional market access strategy that creates patient access. This individual analyzes the market in terms of coverage and reimbursement, existing and emerging payer policies, formulary listings, competitive landscape, trends, pricing, contracting strategies, potential barriers to provider and patient access.  This leader informs and influences key opinion leaders within our target organizations and accounts, regarding improved outcomes and public policy matters.</span> <br> <br><span data-contrast="auto">This position will be responsible for developing a comprehensive engagement strategy and tactical plan to establish payer formulary coverage and access within key accounts with the objective of removing any reimbursement or access barriers for Olema’s launch products.  </span></p>

<p><span data-contrast="auto">More specifically, the Senior Director, National and Strategic Accounts is a key Market Access leadership role responsible for driving the growth and profitability of the organization by developing and executing strategic plans, initiatives and programs related to strategic / national account management (i.e., Regional and National payers, Large Healthcare Systems).  The leader will be responsible for initially supporting a successful US launch of palazestrant in ER+/HER2- metastatic breast cancer and future products through payer formulary access and coverage, strategic corporate partnerships, and health system business partnerships.</span><span data-ccp-props="{}"> </span></p>

<p><span data-contrast="auto">Due to the nature of this role and the requirement to meet with customers, this position will be remote and will require up to 50%</span><strong><span data-contrast="auto"> travel</span></strong><span data-contrast="auto">.</span></p>

<p><span data-contrast="auto">Your work will </span><em><span data-contrast="auto">primarily</span></em><span data-contrast="auto"> encompass:</span><span data-ccp-props="{}"> </span></p>

<ul>

<li data-leveltext="" data-font="Symbol" data-listid="5" data-list-defn-props="{"335552541":1,"335559685":720,"335559991":360,"469769226":"Symbol","469769242":[8226],"469777803":"left","469777804":"","469777815":"multilevel"}" data-aria-posinset="1" data-aria-level="1"><span data-contrast="auto">Leads and inspires a team of national account directors focused on achieving the Market Access objectives established for the brand and the organization.</span><span data-ccp-props="{"134233117":true,"134233118":true,"335557856":16777215}"> </span></li>

</ul>

<ul>

<li data-leveltext="" data-font="Symbol" data-listid="5" data-list-defn-props="{"335552541":1,"335559685":720,"335559991":360,"469769226":"Symbol","469769242":[8226],"469777803":"left","469777804":"","469777815":"multilevel"}" data-aria-posinset="2" data-aria-level="1"><span data-contrast="auto">Collaborates with commercial leadership and executive management to develop and refine the company’s payer and organized customer access strategy and provide input on product and service offerings, pricing, and contracting.</span><span data-ccp-props="{"134233117":true,"134233118":true,"335557856":16777215}"> </span></li>

</ul>

<ul>

<li data-leveltext="" data-font="Symbol" data-listid="5" data-list-defn-props="{"335552541":1,"335559685":720,"335559991":360,"469769226":"Symbol","469769242":[8226],"469777803":"left","469777804":"","469777815":"multilevel"}" data-aria-posinset="3" data-aria-level="1"><span data-contrast="auto">Informs organization of trends and market insights, risks, opportunities for success etc.</span><span data-ccp-props="{"134233117":true,"134233118":true,"335557856":16777215}"> </span></li>

</ul>

<ul>

<li data-leveltext="" data-font="Symbol" data-listid="5" data-list-defn-props="{"335552541":1,"335559685":720,"335559991":360,"469769226":"Symbol","469769242":[8226],"469777803":"left","469777804":"","469777815":"multilevel"}" data-aria-posinset="4" data-aria-level="1"><span data-contrast="auto">Recruit, train, and manage team of Payer/GPO/Organized customer account professionals.</span><span data-ccp-props="{"134233117":true,"134233118":true,"335557856":16777215}"> </span></li>

</ul>

<ul>

<li data-leveltext="" data-font="Symbol" data-listid="5" data-list-defn-props="{"335552541":1,"335559685":720,"335559991":360,"469769226":"Symbol","469769242":[8226],"469777803":"left","469777804":"","469777815":"multilevel"}" data-aria-posinset="5" data-aria-level="1"><span data-contrast="auto">Partners with Market Access Payer Marketing, Trade and Channel management, Patient Support Services and Marketing to develop customer pull through strategies and initiatives that support formulary placement and coverage.</span><span data-ccp-props="{"134233117":true,"134233118":true,"335557856":16777215}"> </span></li>

</ul>

<ul>